Tavapadon: What We Know So Far
A new treatment option for Parkinson’s disease has recently been approved in the United States, and EOPD Ireland is currently seeking information on the pathway for tavapadon to become available in Ireland. We are looking into the anticipated European and Irish regulatory process, including whether and when tavapadon may receive European authorisation, the subsequent Irish approval and reimbursement processes, and what estimated timelines may apply before it could become available to people with Parkinson’s in Ireland.
We will keep our community updated as we become aware of further developments.
Please note: Tavapadon is currently approved by the U.S. Food and Drug Administration (FDA). Its availability in Ireland will depend on the relevant European and Irish regulatory and reimbursement processes. It is not yet possible to confirm an Irish availability date.
What is Tavapadon?
Tavapadon is a once-daily oral medication being developed to treat the motor symptoms of Parkinson’s disease.
In September 2026, the U.S. Food and Drug Administration (FDA) approved tavapadon, which will be marketed in the United States under the brand name Juvmo.
Tavapadon belongs to a class of Parkinson’s medicines known as dopamine agonists. These medicines work by mimicking the action of dopamine in the brain, helping to improve symptoms such as slowness of movement, stiffness and tremor.
What makes tavapadon particularly interesting is that it is designed to selectively target the D1 dopamine receptor, which is involved in the brain circuits responsible for movement.
Information in this article has been informed by information published by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
How does Tavapadon work?
Parkinson’s disease is associated with a loss of dopamine-producing cells in the brain. Levodopa works by providing the brain with a substance that can be converted into dopamine, while dopamine agonists work differently by mimicking the action of dopamine.
Earlier dopamine agonists can act on several different dopamine receptors and brain pathways. This can help with motor symptoms but can also contribute to side effects such as:
- Daytime sleepiness
- Sudden sleep attacks
- Hallucinations
- Impulse control disorders
Tavapadon has been designed to work more selectively on the D1 dopamine receptor, with the aim of targeting the movement-related pathways of the brain.
This raises the possibility that tavapadon could provide motor symptom control with a different side-effect profile to older dopamine agonists.
However, it is important to stress that tavapadon has not been directly compared with other dopamine agonists in clinical trials, and longer-term studies are still underway. It is therefore too early to conclude that it will necessarily have fewer or less severe side effects than existing treatments.
What did the clinical trials show?
The FDA approval of tavapadon was supported by the TEMPO clinical trial programme, which included Phase III studies looking at people at different stages of Parkinson’s.
TEMPO-1 and TEMPO-2
These trials looked at people with earlier-stage Parkinson’s, including people who had been diagnosed within the previous three years and were not taking dopamine medications such as levodopa.
Compared with placebo, tavapadon was associated with improvements in motor symptoms, including:
- Tremor
- Stiffness
- Slowness of movement
- Ability to carry out everyday activities
TEMPO-3
TEMPO-3 looked at people with more advanced Parkinson’s who were already taking levodopa and experiencing “off” time – periods when Parkinson’s symptoms return as medication wears off.
When tavapadon was added to levodopa, participants experienced, on average:
- Approximately one additional hour of “on” time each day without troublesome dyskinesia
- Approximately one hour less “off” time per day
These findings are potentially significant for people whose symptoms are becoming increasingly difficult to control throughout the day.
What are the possible side effects?
Across the clinical trials, tavapadon was generally tolerated by participants.
Reported side effects included:
- Nausea
- Headache
- Dizziness
In people with more advanced Parkinson’s taking tavapadon alongside levodopa, other side effects included dyskinesia, low blood pressure when standing (orthostatic hypotension) and hallucinations.
Impulse control disorders and daytime sleepiness appeared to occur less frequently than has been reported with some older dopamine agonists, although these effects were still observed.
Importantly, longer-term safety data are still being collected. An ongoing study called TEMPO-4 is designed to provide additional information about the longer-term benefits, safety and side-effect profile of tavapadon.
What could Tavapadon mean for people with Parkinson’s?
Tavapadon represents another potential option for managing Parkinson’s motor symptoms, both for people who are recently diagnosed and for people who have been living with Parkinson’s for longer.
For some people, having another treatment option could be particularly valuable if existing medications are no longer providing adequate symptom control or are causing difficult side effects.
However, a new treatment does not automatically mean it will be the right treatment for everyone. As with any Parkinson’s medication, decisions about whether tavapadon is appropriate would need to be made between an individual and their Parkinson’s care team.
When will Tavapadon be available in Ireland?
This is something EOPD Ireland is currently looking into.
FDA approval in the United States does not mean that a medicine automatically becomes available in Ireland. For a new medicine to become available to patients in Ireland, there are a number of stages involved, including the relevant European regulatory authorisation, followed by the processes required for its availability and potential reimbursement in Ireland.
EOPD Ireland is currently seeking clarification on:
- The anticipated European regulatory pathway for tavapadon
- Whether an application for European authorisation has been made and/or its expected timeframe
- The likely timeline for potential Irish availability
- The process for pricing and reimbursement in Ireland
- What this could mean for people with Parkinson’s who may potentially benefit from the treatment
At this stage, we do not have a confirmed Irish availability date.
We will continue to follow developments and keep the EOPD Ireland community posted as more information becomes available.
Information source
The information is provided for general awareness and education and should not be taken as medical advice. Anyone interested in tavapadon should discuss treatment options with their neurologist or Parkinson’s care team.